The approval of benralizumab (Fasenra) is supported by evidence from the phase 3 TATE study. The FDA has approved benralizumab (Fasenra) for children aged 6 to 11 years with severe eosinophilic asthma ...

We removed a statement that benralizumab is not recommended if neither mepolizumab nor reslizumab is recommended. The statement was not needed because if asthma does not meet the criteria for using ...

Please provide your email address to receive an email when new articles are posted on . The interleukin-5 inhibitor benralizumab yielded durable remission rates in EGPA. The drug showed no new safety ...

Add Yahoo as a preferred source to see more of our stories on Google. Researchers say a new way of treating serious asthma and chronic obstructive pulmonary disease attacks could be a ‘game-changer’ ...

Benralizumab, an interleukin-5 (IL-5) antagonist used to treat severe asthma, does not weaken antibody response of influenza vaccinations, according to results of a recent study. Benralizumab, an ...

Add Yahoo as a preferred source to see more of our stories on Google. London scientists have created a “game-changing” new treatment for asthma attacks (File picture) (PA Archive) Benralizumab is the ...

A first treatment has been found for chronic asthma in 50 years and could be “game changing” in preventing deadly attacks. Scientists have discovered benralizumab could tackle suffocating attacks for ...

Benralizumab uniquely targets and rapidly depletes eosinophils and is the first respiratory biologic with an 8-week maintenance dosing schedule Recommendation based on extensive Phase III programme ...

AstraZeneca today announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase III ...

The appraisal committee considered evidence submitted by AstraZeneca and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.

A new treatment for asthma attacks is being described as “game-changing” by the London scientists who created it. The drug, which is called benralizumab, is the first new treatment for asthma attacks ...